Document Classification

Section Type: RESULTS

Text: Agomelatine significantly reduced mean (SD) HARS total score (agomelatine-placebo difference : 4. 71 [1. 03], P <. 0001) and had significant effects on secondary outcome measures, including psychic and somatic HARS subscales, response rate (estimate [standard error]) (agomelatine-placebo difference : 27. 4 % [5. 9 %], P <. 0001), remission on the HARS (agomelatine-placebo difference : 16. 8 % [5. 4 %], P =. 002), Clinical Global Impressions-Severity of Illness scale (CGI-S) (P <. 001), functional impairment (P <. 0001), and sleep quality (P <. 001).